Suzhou, Jiangsu, China | Fund Name | Location |
| Atrinum. | Ventures | Switzerland, Zug, Zug |
| Documentum | California, Pleasanton, United States |
| InterGen Capital | Alberta, Calgary, Canada |
| LenoMed Medical | China, Shanghai |
| Management Solutions | Community of Madrid, Madrid, Spain |
| MEDTEQ | Canada, Montreal, Quebec |
| Pamica NV | Antwerp, Antwerpen, Belgium |
| Praktikerinvest | Stockholm, Stockholm County, Sweden |
| Runway Venture Partners | New York, New York, United States |
| Shanghai Jianxin Kangying Venture Capital Management | China, Shanghai |
| Shanghai Jingzhi Enterprise Management | China, Shanghai |
| Stanford University | California, Stanford, United States |
| theConstruct | Amsterdam, Noord-Holland, The Netherlands |
| Transformational Healthcare Opportunity | - |
| V Ventures | California, San Francisco, United States |
| Venture Products Group | - |
| Vision Asset Management | Seoul, Seoul-t'ukpyolsi, South Korea |
| Walmart | Arkansas, Bentonville, United States |
| WTP Capital | Falls Church, United States, Virginia |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Huaxian Pharmaceutical | $23M | 01 Sep 2021 | Guangdong, Tianjin, China | ||
Zhongzhi.CN | $463K | 09 Sep 2015 | Gusu District, Jiangsu, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Huaxian Pharmaceutical | $23M | 01 Sep 2021 | Guangdong, Tianjin, China | ||
Zhongzhi.CN | $463K | 09 Sep 2015 | Gusu District, Jiangsu, China |
